BNT162b2或全剂量mRNA-1273首次加强免疫的免疫原性与反应原性:一项针对≥75岁成人的随机VACCELERATE试验(EU-COVAT-1)
EU-COVAT-1-AGED A部分是一项随机对照适应性多中心II期试验,53名≥75岁成人随机接种全剂量mRNA-1273(100 µg)或BNT162b2(30 µg)作为第三剂(首次加强)。接种后14天两组抗RBD IgG滴度均达2倍升高,mRNA-1273组几何平均滴度更高,对25种变异株中23种的中和能力更高,安全性总体相似。
要点
- ≥75岁成人第三剂接种BNT162b2或mRNA-1273后14天均达到2倍抗RBD IgG滴度升高。
- 全剂量mRNA-1273组D14抗RBD IgG几何平均滴度为10711 IU/mL(95%CI 8003;14336),高于BNT162b2组的7090 IU/mL(95%CI 5688;8837)。
- 全剂量mRNA-1273对野生型及25种受试变异株中23种显示更高的中和能力,总体安全性相似。
核心结论
- 第三剂BNT162b2或mRNA-1273在接种后14天均使≥75岁成人循环抗体大幅升高。
- 全剂量mRNA-1273提供更高的抗体水平,总体安全性相似。
研究设计与样本
- EU-COVAT-1-AGED A部分为随机对照、适应性、多中心II期试验,评估≥75岁个体第三剂(首次加强)的安全性和免疫原性。
- 53名参与者随机接受全剂量mRNA-1273(Spikevax®,100 µg)或BNT162b2(Comirnaty®,30 µg)。
- 主要终点为接种后14天经定量电化学发光(ECL)免疫分析法测定的针对武汉野生型SARS-CoV-2 RBD区域的循环抗体滴度2倍升高率。
主要发现
- 2021年11月8日至2022年1月4日期间,53名≥75岁参与者接种COVID-19疫苗作为首次加强。
- 50名受试者(BNT162b2 n=25/mRNA-1273 n=25)纳入第14天免疫原性分析。
- 所有受试者均达到接种后14天抗RBD IgG滴度2倍升高的主要终点。
- D14抗RBD IgG几何平均滴度:mRNA-1273组10711 IU/mL(95%CI 8003;14336)vs BNT162b2组7090 IU/mL(95%CI 5688;8837)。
- 全剂量mRNA-1273对野生型及25种受试变异株中23种显示更高的中和能力。
关键数值与推荐
- 主要终点:接种后14天抗RBD IgG滴度2倍升高率,所有受试者均达到。
- D14抗RBD IgG几何平均滴度:mRNA-1273组10711 IU/mL(95%CI 8003;14336)vs BNT162b2组7090 IU/mL(95%CI 5688;8837)。
- 中和能力:全剂量mRNA-1273对野生型及25种受试变异株中23种显示更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccination remains crucial for protection against severe SARS-CoV-2 infection, especially for people of advanced age, however, optimal dosing regimens are as yet lacking. METHODS: EU-COVAT-1-AGED Part A is a randomised controlled, adaptive, multicentre phase II trial evaluating safety and immunogenicity of a 3rd vaccination (1st booster) in individuals ≥75 years. Fifty-three participants were randomised to full-doses of either mRNA-1273 (Spikevax®, 100 µg) or BNT162b2 (Comirnaty®, 30 µg). The primary endpoint was the rate of 2-fold circulating antibody titre increase 14 days post-vaccination measured by quantitative electrochemiluminescence (ECL) immunoassay, targeting RBD region of Wuhan wild-type SARS-CoV-2. Secondary endpoints included the changes in neutralising capacity against wild-type and 25 variants of concern at 14 days and up to 12 months. Safety was assessed by monitoring of solicited adverse events (AEs) for seven days after on-study vaccination. Unsolicited AEs were collected until the end of follow-up at 12 months, SAEs were pursued for a further 30 days. RESULTS: Between 08th of November 2021 and 04th of January 2022, 53 participants ≥75 years received a COVID-19 vaccine as 1st booster. Fifty subjects (BNT162b2 n = 25/mRNA-1273 n = 25) were included in the analyses for immunogenicity at day 14. The primary endpoint of a 2-fold anti-RBD IgG titre increase 14 days after vaccination was reached for all subjects. A 3rd vaccination of full-dose mRNA-1273 provided higher anti-RBD IgG titres (Geometric mean titre) D14 mRNA-127310711 IU/mL (95 %-CI: 8003;14336) vs. BNT162b2: 7090 IU/mL (95 %-CI: 5688;8837). We detected a pattern showing higher neutralising capacity of full-dose mRNA-1273 against wild-type as well as for 23 out of 25 tested variants. INTERPRETATION: Third doses of either BNT162b2 or mRNA-1273 provide substantial circulating antibody increase 14 days after vaccination. Full-dose mRNA-1273 provides higher antibody levels with an overall similar safety profile for people ≥75 years. FUNDING: This trial was funded by the European Commission (Framework Program HORIZON 2020).
引用
- Neuhann JM, Stemler J, Carcas AJ, et al. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1). Vaccine. 2023. PMID: 37919141. doi:10.1016/j.vaccine.2023.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。